Department of Cardiovascular Diseases, Vita Salute University and San Raffaele Hospital, Milan, Italy.
Department of Cardiovascular Diseases, Vita Salute University and San Raffaele Hospital, Milan, Italy, and Prevention and Rehabilitation Unit, Fondazione Don Gnocchi, Parma, Italy,
Front Biosci (Landmark Ed). 2017 Jun 1;22(10):1724-1749. doi: 10.2741/4568.
The study of biomarkers and their related signalling pathways has allowed the development of new therapeutic strategies in a range of disorders. However, in hypertrophic cardiomyopathy (HCM), which is the most common hereditary cardiac disease, there are many potential biomarkers described, but their specificity and applicability for HCM remains an open field. The aim of the present review is to provide an overview of molecules that could give some insight into the pathophysiologic mechanisms underlying HCM, especially to those with "theranostic" - a combination of diagnostics and therapy - potential. The clinical and pre-clinical state of the art and theranostic perspectives of this topic will be part of the current discussion. The better understanding of this subject would provide an algorithm, to optimize the integration of diagnosis, prognostics and therapeutics findings in HCM, leading to a tailored approach for this pathology.
生物标志物及其相关信号通路的研究已经为一系列疾病的新治疗策略的发展提供了可能。然而，在肥厚型心肌病（HCM）中，尽管有许多描述的潜在生物标志物，但它们在 HCM 中的特异性和适用性仍然是一个未解决的问题。本综述的目的是提供对可能为 HCM 潜在病理生理机制提供一些见解的分子的概述，特别是对那些具有“治疗诊断学”（诊断和治疗相结合）潜力的分子。本主题的临床和临床前现状和治疗诊断学观点将是当前讨论的一部分。更好地理解这一主题将提供一个算法，以优化 HCM 中诊断、预后和治疗发现的整合，从而为这种病理提供一种个性化的方法。
